CDMOのチャート
CDMOの企業情報
| symbol | CDMO |
|---|---|
| 会社名 | Avid Bioservices Inc （ペレグリン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アビッド・バイオサービシズ（Avid Bioservices Inc.）（旧名：Peregrine Pharmaceuticals Inc.）は、癌の治療・診断用モノクローナル抗体を開発するバイオ医薬品会社。同社の治験モノクローナル抗体のパイプラインはホスファチジルセリン（PS）を標的とする抗体、及びデオキシリボ核酸（DNA）・ヒストン標的とする抗体を含む2つの技術プラットフォームに基づく。「Bavituximab」は同社のPSを標的とする抗体である。「Bavituximab」は治療可能性を明示し、癌の治療に対する新しい方法を示す。「PGN650」はPSを標的とする造影剤であり、癌造影の新しい方法が望まれる。同社は第一・第二選択非小細胞肺がんと第一選択膵臓がんのための標準的化学療法と組み合わせる「Bavituximab」の3つのランダム化第II相試験を実行している。同社は「Bavituximab」に関する会社提供の試験の他、異なる併用療法と腫瘍適応に関する治験責任医師提供の試験4つを有している。 ペレグリン・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。ホスファチジルセリンを標的とする技術プラットフォ―ムに基づき、癌の治療および診断に焦点を当て、臨床試験における薬剤候補を研究、開発する。同社の鍵となる免疫療法候補、バビツキシマブ(bavituximab)は、非小細胞肺癌などの治療のために開発中である。 Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization |
| 本社所在地 | 2642 Michelle Drive Suite 200 Tustin CA 92780 USA |
| 代表者氏名 | Roger J. Lias ロジャー・リアス |
| 代表者役職名 | President Chief Executive Officer |
| 電話番号 | +1 714-508-6100 |
| 設立年月日 | 29738 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 186人 |
| url | www.peregrineinc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cdmo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -21.61700 |
| 終値（lastsale） | 5.74 |
| 時価総額（marketcap） | 321448357.44 |
| 時価総額 | 時価総額（百万ドル） 312.48810 |
| 売上高 | 売上高（百万ドル） 39.13300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 275.09910 |
| 当期純利益 | 当期純利益（百万ドル） -30.01000 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 31 July 2018 Avid Bioservices Inc revenues decreased 54% to $12.6M. Net loss applicable to common stockholders excluding extraordinary items totaled $3.4M vs. income of $1.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Interest and other expense increase from $3K to $11K (expense). |
CDMOのテクニカル分析
CDMOのニュース
Monoclonal Antibodies? Avid Bioservices Surges 32% On Blowout Q3 2023/03/15 21:30:50 ValueWalk
Avid Bioservices manufactures monoclonal antibodies and various biologics for biotech and pharmaceutical companies. The company hit record revenues in fiscal Q3 2023, up 21% YoY achieving non-GAAP profitability. Avid is adding manufacturing capacity with a new facility planned to open in Spring 2023. Avid Bioservices trade at 8X forward earnings and has a 7.59% short […]
Why Avid Bioservices Stock Is Surging Today 2023/03/14 16:35:47 The Motley Fool
The bio-manufacturer''s ongoing expansion efforts are a hit with investors.
Avid Bioservices adds 34% after Q3 beat as KeyBanc upgrades 2023/03/14 14:46:43 Seeking Alpha
Avid Bioservices (CDMO) gained ~34% on Tuesday morning after the contract manufacturer reported better-than-expected financials for Q3 FY23, prompting KeyBanc to upgrade it.
PaxMedica, Avid Bioservices top healthcare gainers; Rapt, Unicycive lead losers'' pack 2023/03/14 14:08:44 Seeking Alpha
PaxMedica (PXMD) +36%. Avid Bioservices (CDMO) +25%. Rapt Therapeutics, (RAPT) -23%. Unicycive Therapeutics (UNCY) -16%.
KeyBanc Upgrades Avid Bioservices to Overweight 2023/03/14 06:13:04 Investing.com
https://www.investing.com/news/pro/keybanc-upgrades-avid-bioservices-to-overweight-432SI-3029586
Avid Bioservices Earnings Perspective: Return On Invested Capital 2022/09/15 14:03:46 Benzinga
According to Benzinga Pro data Avid Bioservices (NASDAQ: CDMO ) posted a 98.65% decrease in earnings from Q4. Sales, however, increased by 17.5% over the previous quarter to $36.69 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Avid Bioservices is not utilizing their capital as effectively as possible. Avid Bioservices reached earnings of $115.60 million and sales of $31.23 million in Q4. What Is Return On Invested Capital? Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly … Full story available on Benzinga.com
Analysts Predicting A Spike In Avid Bioservices Inc. (NASDAQ: CDMO)? 2022/09/10 13:30:00 Stocks Register
Avid Bioservices Inc. (NASDAQ:CDMO) price on Friday, September 09, rose 6.45% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $18.33. A look at the stock’s price movement, the close in the last trading session was $17.22, moving within a range at $17.35 and $18.40. The beta value … Analysts Predicting A Spike In Avid Bioservices Inc. (NASDAQ: CDMO)? Read More »
Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference 2022/09/07 20:05:00 GlobeNewswire
TUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Morgan Stanley 20 th Annual Global Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place September 12-14, 2022, in New York City.
Avid Bioservices, Inc. (CDMO) Q1 2023 Earnings Call Transcript 2022/09/07 01:57:08 Seeking Alpha
Avid Bioservices, Inc. (NASDAQ:NASDAQ:CDMO) Q1 2023 Earnings Conference Call September 6, 2022 16:30 ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief…
Avid Bioservices Earnings Miss, Revenue Beats In Q1 By Investing.com 2022/09/06 23:29:00 Investing.com
Avid Bioservices Earnings Miss, Revenue Beats In Q1
Avid Bioservices'' (CDMO) CEO Nick Green on Q3 2022 Results - Earnings Call Transcript 2022/03/09 02:09:01 Seeking Alpha
Avid Bioservices GAAP EPS of $0.04 in-line, revenue of $31.51M beats by $6.2M 2022/03/08 21:17:17 Seeking Alpha
Avid Bioservices press release (CDMO): Q3 GAAP EPS of $0.04 in-line.Revenue of $31.51M (+44.5% Y/Y) beats by $6.2M.Guidance: The company is reiterating revenue guidance for fiscal…